Intrexon Corporation (NYSE:XON)‘s stock had its “buy” rating reissued by research analysts at Northland Securities in a note issued to investors on Friday. They currently have a $21.00 target price on the biotechnology company’s stock. Northland Securities’ price target indicates a potential upside of 77.82% from the company’s current price.
Several other research analysts also recently commented on XON. Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. JMP Securities restated an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research note on Thursday, October 5th. Griffin Securities restated a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research note on Friday, October 6th. Finally, Stifel Nicolaus boosted their price target on Intrexon Corporation from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $38.50.
Intrexon Corporation (NYSE XON) opened at $11.81 on Friday. The company has a current ratio of 2.45, a quick ratio of 2.25 and a debt-to-equity ratio of 0.01. Intrexon Corporation has a one year low of $11.80 and a one year high of $32.90.
Intrexon Corporation (NYSE:XON) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 18.59% and a negative net margin of 66.88%. The company had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. During the same period in the previous year, the company posted ($0.42) EPS. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. research analysts predict that Intrexon Corporation will post -0.84 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Intrexon Corporation (XON) Stock Rating Reaffirmed by Northland Securities” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/intrexon-corporation-xon-stock-rating-reaffirmed-by-northland-securities.html.
In related news, Director Robert B. Shapiro bought 2,850 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was purchased at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the transaction, the director now owns 43,157 shares in the company, valued at approximately $755,247.50. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Andrew J. Last bought 2,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were bought at an average price of $19.99 per share, with a total value of $39,980.00. Following the completion of the transaction, the chief operating officer now owns 2,000 shares in the company, valued at approximately $39,980. The disclosure for this purchase can be found here. Insiders own 55.10% of the company’s stock.
Several large investors have recently added to or reduced their stakes in XON. UBS Asset Management Americas Inc. lifted its position in shares of Intrexon Corporation by 16.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock valued at $661,000 after acquiring an additional 4,773 shares during the period. Teachers Advisors LLC lifted its position in shares of Intrexon Corporation by 6.8% during the 1st quarter. Teachers Advisors LLC now owns 53,606 shares of the biotechnology company’s stock valued at $1,062,000 after acquiring an additional 3,434 shares during the period. Legal & General Group Plc lifted its position in shares of Intrexon Corporation by 102.5% during the 1st quarter. Legal & General Group Plc now owns 18,450 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 9,340 shares during the period. Vanguard Group Inc. lifted its position in shares of Intrexon Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after acquiring an additional 226,090 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Intrexon Corporation by 3.5% during the 1st quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock valued at $8,513,000 after acquiring an additional 14,674 shares during the period. Hedge funds and other institutional investors own 82.10% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.